Bunitrolol HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414261

CAS#: 23093-74-5 (HCl)

Description: Bunitrolol HCl is the salt form of Bunitrolol Free Base, a beta-adrenergic receptor antagonist with weak antiarrhythmic activity and minor ability to decrease the heart rate.

Chemical Structure

img
Bunitrolol HCl
CAS# 23093-74-5 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 414261
Name: Bunitrolol HCl
CAS#: 23093-74-5 (HCl)
Chemical Formula: C14H21ClN2O2
Exact Mass: 0.00
Molecular Weight: 284.780
Elemental Analysis: C, 59.05; H, 7.43; Cl, 12.45; N, 9.84; O, 11.24

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 23093-74-5 (HCl); 34915-68-9 (free base)  

Synonym: Bunitrolol hydrochloride; Bunitrolol HCl; KO1366; KO-1366; KO 1366

IUPAC/Chemical Name: 2-(3-tert-Butylamino-2-hydroxypropoxy)benzonitrile hydrochloride

InChi Key: RJPWESHPIMRNNM-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H20N2O2.ClH/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15;/h4-7,12,16-17H,9-10H2,1-3H3;1H

SMILES Code: N#CC1=CC=CC=C1OCC(O)CNC(C)(C)C.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 284.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Narimatsu S, Mizukami T, Huang Y, Masubuchi Y, Suzuki T. In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. J Pharm Pharmacol. 1996 Nov;48(11):1185-9. PubMed PMID: 8961170.

2: Ono S, Tsutsui M, Gonzalez FJ, Satoh T, Masubuchi Y, Horie T, Suzuki T, Narimatsu S. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics. 1995 Apr;5(2):97-102. PubMed PMID: 7663534.

3: Okabayashi T, Naito S, Arakawa K. Antihypertensive effect of intravenously and orally administered bunitrolol (Kö 1366). Arzneimittelforschung. 1979;29(9):1417-21. PubMed PMID: 42418.

4: Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull. 1994 Jun;17(6):803-7. PubMed PMID: 7951142.

5: Narimatsu S, Gotoh M, Masubuchi Y, Horie T, Ohmori S, Kitada M, Kageyama T, Asaoka K, Yamamoto I, Suzuki T. Stereoselectivity in bunitrolol 4-hydroxylation in liver microsomes from marmosets and Japanese monkeys. Biol Pharm Bull. 1996 Nov;19(11):1429-33. PubMed PMID: 8951158.

6: Haddad S, Poulin P, Funk C. Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine. J Pharm Sci. 2010 Oct;99(10):4406-26. doi: 10.1002/jps.22136. PubMed PMID: 20310018.

7: Tsuchihashi H, Aono J, Nagatomo T, Kawada T, Ohta H, Imai S. Effects of bunitrolol on adrenergic and serotonergic receptors. Jpn J Pharmacol. 1987 Nov;45(3):349-56. PubMed PMID: 2893855.

8: Chiba K, Hayase N, Ichihara K. Effects of bunitrolol on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Apr;82(4):384-8. PubMed PMID: 8096874.

9: Tsuchihashi H, Nagotomo T, Imai S. Selectivity of bunitrolol for beta 1- and beta 2-adrenergic receptors and 5HT1B-receptors: assessment by biphasic Scatchard plots and biphasic displacement curve analysis with 125I-iodocyanopindolol and 3H-CGP12177. Jpn J Pharmacol. 1989 Jun;50(2):93-100. PubMed PMID: 2570175.

10: Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90. PubMed PMID: 10206323.

11: Ishida R, Fujita S, Suzuki T. Bunitrolol metabolism and its inhibition by cimetidine. J Pharm Pharmacol. 1988 Jan;40(1):64-5. PubMed PMID: 2896780.

12: Beumer HM, Ritter W. Antagonism of fenoterol against beta-blocking drugs bunitrolol and practolol in asthmatics. Respiration. 1975;32(5):363-7. PubMed PMID: 241102.

13: Kawashima K, Miwa Y, Fujimoto K, Matsumoto J, Kimura M, Nagakura A. Hypotensive effect of bunitrolol at low plasma concentrations in conscious, unrestrained spontaneously hypertensive rats. Jpn J Pharmacol. 1985 Jul;38(3):259-65. PubMed PMID: 2865388.

14: Jonker JJ, de Klerk J, den Ottolander GJ. A double blind cross-over comparison of bunitrolol and placebo in the treatment of angina pectoris. Arzneimittelforschung. 1981;31(7):1140-2. PubMed PMID: 6115654.

15: Fujita S, Masuda M, Shimamoto Y, Hoshi H, Kariya S, Kazusaka A, Suzuki T. Effect of 3-methylcholanthrene on bunitrolol metabolism. Kinetics and immunological studies on 4-hydroxylation of bunitrolol catalyzed by two species of cytochromes P450 in rat liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):254-9. PubMed PMID: 8742239.

16: Satoh K, Nunoki K, Goto T, Taira N. The mechanism underlying the vasodilator action of bunitrolol: contribution of alpha 1-adrenoceptor blocking action. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):508-15. PubMed PMID: 2410682.

17: Masubuchi Y, Yamamoto K, Suzuki T, Horie T, Narimatsu S. Characterization of the oxidation reactions catalyzed by CYP2D enzyme in rat renal microsomes. Life Sci. 1996 May 24;58(26):2431-7. PubMed PMID: 8691988.

18: Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Effects of bunitrolol on myocardial contractility and left ventricular myosin isoenzyme pattern. Arzneimittelforschung. 1988 Sep;38(9):1280-2. PubMed PMID: 2906244.

19: Narimatsu S, Huang Y, Mizukami T, Masubuchi Y, Suzuki T. Development of a high-performance liquid chromatographic method for the analysis of enatiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes. Anal Biochem. 1994 Oct;222(1):256-61. PubMed PMID: 7856858.

20: Serizawa T, Iizuka M, Ohya T, Ohtani Y, Sugiura S, Koide T, Uchida Y, Morooka S, Kato A, Kimura Y, et al. Hemodynamic effect of bunitrolol on patients with ischemic heart disease. Comparison with propranolol. Jpn Heart J. 1987 May;28(3):367-75. PubMed PMID: 2887672.